Share

January 28, 2020; 94 (4) ArticleOpen Access

Clinical risk factors in SUDEP

A nationwide population-based case-control study

Olafur Sveinsson, Tomas Andersson, Peter Mattsson, Sofia Carlsson, Torbjörn Tomson
First published December 12, 2019, DOI: https://doi.org/10.1212/WNL.0000000000008741
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
4795

Share

This article has a correction. Please see:

Article Information

vol. 94 no. 4 e419-e429
DOI: 
https://doi.org/10.1212/WNL.0000000000008741
PubMed: 
31831600
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 4, 2019
  • Accepted in final form August 5, 2019
  • First Published December 12, 2019.

Article Versions

Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Olafur Sveinsson, MD, MSc,
    2. Tomas Andersson, BSc,
    3. Peter Mattsson, MD, PhD,
    4. Sofia Carlsson, PhD and
    5. Torbjörn Tomson, MD, PhD
  1. Olafur Sveinsson, MD, MSc,
    2. Scientific Advisory Boards:

    1. 1) Advisory board for Biogen Idec on the medication Plegridy for MS.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Travel funding from Biogen Idec 2) Travel funding from UCB 3) Travel funding from Sandoz

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Consultant for Biogen Idec on Plegridy and Zinbryta.

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Received consulting fees from Biogen, other from Biogen, other from UCB and Sandoz, outside the submitted work.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) The study was supported by Stockholm County Council, GlaxoSmithKline and Citizens United for Research in Epilepsy (CURE).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tomas Andersson, BSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Peter Mattsson, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Meducan Limited

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Uppsala County Council

    Research Support, Foundations and Societies:

    1. Epilepsifonden Selander Foundation CURE (with prof Tomson) Stock/Stock Options, Medical Equipment & Materials: Elekta AB

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sofia Carlsson, PhD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Grants from the Swedish Research Council, Swedish Diabetes Association, Swedish Research Council for social and working life (other research)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Torbjörn Tomson, MD, PhD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (O.S. T.T.), Karolinska University Hospital; Department of Clinical Neuroscience (O.S. T.T.) and Institute of Environmental Medicine (T.A., S.C.), Karolinska Institutet; Center for Occupational and Environmental Medicine (T.A.), Stockholm County Council; and Department of Neuroscience (P.M.), University of Uppsala, Sweden.
  1. Correspondence
    Dr. Sveinsson olafur.sveinsson{at}sll.se

Article usage

Article usage: December 2019 to October 2023

AbstractFullPdfSource
Dec 20194150153Highwire
Jan 2020394780304Highwire
Feb 202061848287Highwire
Mar 202022542146Highwire
Apr 20202226698Highwire
May 20209181102Highwire
Jun 202048176103Highwire
Jul 20202917763Highwire
Aug 20203017391Highwire
Sep 202051331117Highwire
Oct 20203335594Highwire
Nov 202029377100Highwire
Dec 20202227566Highwire
Jan 202129243102Highwire
Feb 20214039774Highwire
Mar 202127392103Highwire
Apr 20213429198Highwire
May 20213324085Highwire
Jun 20213228367Highwire
Jul 20212425084Highwire
Aug 20212824888Highwire
Sep 202137306107Highwire
Oct 202125387119Highwire
Nov 20212734895Highwire
Dec 20213129576Highwire
Jan 202251331111Highwire
Feb 202223337112Highwire
Mar 202247343138Highwire
Apr 20222924386Highwire
May 20222227678Highwire
Jun 20223524260Highwire
Jul 20222524157Highwire
Aug 20223740078Highwire
Sep 20222539987Highwire
Oct 20226752092Highwire
Nov 20225947690Highwire
Dec 20223624265Highwire
Jan 202333458109Highwire
Feb 202350488116Highwire
Mar 20237043385Highwire
Apr 20234628377Highwire
May 20234342990Highwire
Jun 20232837696Highwire
Jul 20232128170Highwire
Aug 20235425299Highwire
Sep 20233029987Highwire
Oct 20232925290Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me

Recommended articles